Key result
The bradykinin antagonist Hoe 140 abolished the lowering effect of both the ACE inhibitor enalaprilat and the ARB candesartan on the lower limit of cerebral blood flow autoregulation.
Why the study?
Does bradykinin antagonism counteract the acute effect of ACE inhibition and ARB on the lower limit of autoregulation of cerebral blood flow in rats?
Does bradykinin antagonism counteract the acute effect of ACE inhibition and ARB on the lower limit of autoregulation of cerebral blood flow in rats?
Bradykinin antagonism counteracts the acute lowering effect of both ACE inhibitors and ARBs on the lower limit of cerebral blood flow autoregulation, suggesting ARBs may also influence intravascular bradykinin.
Answers are grounded in this paper and cite their sources.
Implicates bradykinin in ARB effects on cerebral autoregulation in rats; leaves open human translation.
The lower limit of autoregulation of cerebral blood flow (CBF) can be modulated with both angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARB). The influence of bradykinin antagonism on ARB-induced changes was the subject of this study. CBF was measured in Sprague-Dawley rats with laser Doppler technique. The blood pressure was lowered by controlled bleeding. Six groups of rats were studied: a control group and five groups given drugs intravenously: an ACE inhibitor (enalaprilat), an ARB (candesartan), a bradykinin-2 receptor antagonist (Hoe 140), a combination of enalaprilat and Hoe 140, and a combination of candesartan and Hoe 140. In the control group, the lower limit of CBF autoregulation was 54±9 mm Hg (mean±s.d.), with enalaprilat it was 46±6, with candesartan 39±8, with Hoe 140 53±6, with enalaprilat/Hoe 140 52±6, and with candesartan/Hoe 140 50±7. Both enalaprilat and candesartan lowered the lower limit of autoregulation of CBF significantly. The bradykinin antagonist abolished not only the effect of the ACE inhibitor but surprisingly also the effect of the ARB on the lower limit of CBF autoregulation, the latter suggesting an effect on intravascular bradykinin.
No takes yet. Share an insight, caveat, or question.
Sigurdsson et al. (2013) studied this question. Bradykinin-2 receptor antagonist (Hoe 140) vs. Control, ACE inhibitor (enalaprilat), and ARB (candesartan) was evaluated on Lower limit of autoregulation of cerebral blood flow. The bradykinin antagonist Hoe 140 abolished the lowering effect of both the ACE inhibitor enalaprilat and the ARB candesartan on the lower limit of cerebral blood flow autoregulation.
Synapse has enriched 10 related papers. Consider them for comparative context: